Galapagos NV - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
GLPG Nasdaq 2836 www.glpg.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Galapagos NV

Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update - Feb 12th, 2025 9:01 pm
Galapagos NV (GLPG): A Cheap Biotech Stock to Invest In Now - Feb 12th, 2025 1:03 pm
Galapagos (GLPG) Loses -21.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Feb 5th, 2025 2:35 pm
Galapagos Plans to Split Into Two Entities, Revise Agreement With Gilead Sciences, Reduce Workforce by 40% - Jan 8th, 2025 12:16 pm
Galapagos to Unlock Shareholder Value by Declaring its Intent to Separate into Two Publicly Traded Entities - Jan 8th, 2025 6:30 am
Galapagos to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Jan 7th, 2025 9:01 pm
Galapagos NV (AMS:GLPG) stock most popular amongst retail investors who own 56%, while public companies hold 25% - Dec 13th, 2024 6:16 am
ASH 2024: Galapagos presents positive results for a seven-day ‘vein-to-vein’ CAR T-cell therapy - Dec 11th, 2024 4:00 am
Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma - Dec 7th, 2024 5:30 pm
Galapagos to Present Results of Pioneering Innovation in Cancer Cell Therapy at ASH 2024 - Nov 5th, 2024 9:01 pm
Galapagos Third Quarter 2024 Earnings: €0.74 loss per share (vs €0.39 profit in 3Q 2023) - Nov 2nd, 2024 7:42 am
Galapagos NV (GLPG) Q3 2024 Earnings Call Highlights: Strong Cash Position and R&D Progress ... - Nov 1st, 2024 7:03 am
Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update - Oct 30th, 2024 8:01 pm
Galapagos welcomes Oleg Nodelman to its Board of Directors to support strategic growth - Oct 7th, 2024 5:00 am
Galapagos receives transparency notification from EcoR1 Capital - Sep 30th, 2024 8:01 pm
Galapagos receives transparency notification from FMR LLC - Sep 3rd, 2024 8:01 pm
Even after rising 13% this past week, Galapagos (AMS:GLPG) shareholders are still down 82% over the past five years - Sep 1st, 2024 7:57 am
Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More - Aug 28th, 2024 2:11 pm
Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study - Aug 23rd, 2024 11:43 am
Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma - Aug 23rd, 2024 5:00 am